Set up for success: What have the past 25 years taught us about the future of biopharmaceutical innovation?
The pace of change over the last 25 years has been tremendous. Scientific progress in genetics, drug discovery, novel therapeutics and diagnostics have transformed the outlook for millions of patients with serious diseases. This panel discussion spotlights how innovations across biopharma and academia have contributed to many signature achievements over this period and anticipates how these success stories will inform future breakthroughs.
James Drew, Consultant, Citeline
Andreas Wallnoefer, Partner at Jeito Capital, former Global Head Clinical Research and Head pRED Development F. Hoffmann – La Roche
Burkhard Ludewig, Head Translational Cardioimmunology, University Heart Center Zurich
Ulf Grawunder, Former founder, CEO and Board member of NBE-Therapeutics, currently founder, CEO and Board member T-CURX
Hanns-Christian Mahler, CEO at ten23 health, former Head of Lonza/Drug Product Services, former Head of Roche/Pharmaceutical Development & Supplies Biologics EU
Citeline (a Norstella Company) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory related-decisions and create real-world opportunities for growth.